Skip to content

Brexpiprazole

SGA • Last reviewed 2025-09-23

Brands: Rexulti

Sources updated 2025 • 1 references

Summary

General Information

Indicated for: Schizophrenia; adjunctive therapy to antidepressants for MDD. Second‑generation antipsychotic (SGA)

Dosage & Administration

Typical dose range: 1–4 mg/day

Indications (label)

Schizophrenia; adjunctive therapy to antidepressants for MDD.

View labelExact

Mechanism (brief)

D2/D3 partial agonist; 5‑HT1A partial agonist; 5‑HT2A antagonist.

Metabolism & Half‑life

  • Metabolism: CYP3A4 and CYP2D6; dose adjust with inhibitors/inducers.
  • Half‑life: ~91 h (long).

Therapeutic Drug Monitoring (TDM)

Recommended: No

References